

# High Blood Sugar?

## Don't Take a Risk, Take The R.I.S.C.™



Available Only At Lifespan, the R.I.S.C.™ based Treatment has helped 70% of patients successfully manage their blood sugar level by actively adhering to Lifespan's treatments.

30,000+ Lifespan patients have already taken the R.I.S.C.™ based treatment\*

- R.I.S.C.™ Test**  
Comprehensively screens 30 vital cardiometabolic health indicators and indicates your risk for future health complications.
- Consultation With Diabetologist & Dietician**  
Get 30 minutes dedicated consultations from a diabetologist and dietician based on American Diabetes Association guidelines.
- Advanced Glucorite**  
14 days Painless blood sugar monitoring
- IDHA Test**  
An advanced test to measure your 3 month average blood sugar levels.

Consultations at just **₹600** Discount on medicines\* up to **50%**

\*Valid on Smart Plans up to ₹15,000

Lifespan's R.I.S.C.™ based Treatment Plans

R.I.S.C.™ Vital  
₹5,995 ₹3,995  
Includes test kit and app link

R.I.S.C.™ Smart (6 months)  
₹7,995 ₹5,995  
Includes blood tests with 20 parameters

R.I.S.C.™ Gluco Smart (6 months)  
₹12,495 ₹9,995  
Includes Advanced Gluco Kit, 14 Days Painless blood sugar monitoring

Full Care Diabetes Treatment  
Call: 1800 3000 1892



Visit us at 28/Chilakalurthi, Hyderabad: 240-4023 7771 | Vijayawada: 240-3375 8001 | Bangalore: 080-420 8650 9335 | Madurai: 042-3375 4003 | Madhapur: 040-3318 4008

\* Figures will vary based on individual's compliance. Offer valid on Lifespan's Gluco Kit & Gluco Smart Plan from January 2019 to December 2024, when 1% out of the patients have managed their blood sugar levels. † Medication provided through the app. ‡ On app, we included 40 medicines and included 8 varieties of types of medicines. We included 40 medicines. †† Includes 14 days Painless blood sugar monitoring. ‡ Includes 14 days Painless blood sugar monitoring. ‡ Includes 14 days Painless blood sugar monitoring. ‡ Includes 14 days Painless blood sugar monitoring. ‡ Includes 14 days Painless blood sugar monitoring.

Various Payment Options: Debit Card | Credit Card | Cheque | E-Wallet | Cash

# CINEMA DIARY

## In a fresh pairing, Nawazuddin Siddiqui and Mouni Roy come together for 'Bole Chudiyan'



Bole Chudiyan, featuring Nawazuddin Siddiqui and Mouni Roy, is a fresh pairing in the Hindi film industry. The movie is directed by Anand B. Pant and is set to release on August 12. The film is a romantic comedy and is expected to be a commercial success. Nawazuddin Siddiqui and Mouni Roy are both established actors in the industry and their pairing is highly anticipated. The movie is set to be released on the OTT platform and is expected to have a wide reach.

## HINDUSTAN BIO SCIENCES LIMITED

Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034, Phone No. 23555161, Fax: 040-46205171  
Website: www.hindustanbiosciences.in, e-mail: pharma.hindustanbio@gmail.com, CIN: L28540TG1999PLC013554  
STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022

Sl. No.	Particulars	QUARTER ENDED (Rs. in Lakhs)			
		30.06.2022 (Unaudited)	30.06.2021 (Unaudited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	Income from Operations				
(a)	Revenue from operations	27.14	0.27	16.42	43.95
(b)	Other Income	-	-	-	0.26
(c)	Total Revenue (1)	27.14	0.27	16.42	44.21
2	Expenses				
(a)	Cost of material consumed	-	-	13.05	28.85
(b)	Changes in inventories of finished goods, stock in trade and stock in progress	-	-	-	-
(c)	Employee Benefit Expenses	3.93	5.94	6.04	24.03
(d)	Finance Costs	0.03	0.02	0.07	0.50
(e)	Selling Expenses	0.03	-	0.23	0.01
(f)	Depreciation and amortisation Expenses	3.10	0.10	0.08	0.34
(g)	Other Expenses	4.82	32.13	7.20	45.97
(h)	Total Expenses (2)	25.95	38.45	26.67	100.24
3	Profit/(Loss) before Exceptional & Extraordinary items and tax (1-2)	(2.81)	(38.18)	(7.84)	(57.49)
4	Exceptional items	-	-	-	-
5	Profit/(Loss) before tax(3+4)	(2.81)	(38.18)	(7.84)	(57.49)
6	Tax Expenses	-	-	-	-
(a)	Current Tax	-	-	-	0.03
(b)	Deferred Tax	-	0.54	-	0.30
7	Profit/(Loss) for the period from continuing operations (5-6)	(2.81)	(37.64)	(7.84)	(57.19)
8	Expenses of discontinued operations	-	-	-	-
9	Profit/(Loss) from discontinued operations after tax (8-9)	-	-	-	-
10	Profit/(Loss) for the period (7+9)	(2.81)	(37.64)	(7.84)	(57.19)
11	Other Comprehensive Income				
(A)	Items that will not be reclassified to profit or loss	-	-	-	-
(1)	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
(2)	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
(B)	Items that will be reclassified to profit or loss	-	-	-	-
(1)	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
12	Total Comprehensive Income for the period (11+12)	(2.81)	(37.64)	(7.84)	(57.19)
13	Net Profit/(Loss) after tax and other comprehensive income for the period	(2.81)	(37.64)	(7.84)	(57.19)
14	Net Profit/(Loss) after tax and other comprehensive income for the period (13-14)	1,025.08	1,025.08	1,025.08	1,025.08
15	Revenue earned from operations	-	-	-	(346.57)
16	Expenses per equity share for continuing operations				
(A) Basic	(0.02)	(0.38)	(0.07)	(0.30)	
(B) Diluted	(0.02)	(0.38)	(0.07)	(0.30)	
17	Earnings per equity share for discontinued operations				
(A) Basic	-	-	-	-	
(B) Diluted	-	-	-	-	
18	Earnings per equity share for discontinued & continuing operations				
(A) Basic	(0.02)	(0.38)	(0.07)	(0.30)	
(B) Diluted	(0.02)	(0.38)	(0.07)	(0.30)	

NOTES:  
1. The Un-Audited Financial Results were taken on record by the Board of Directors in their meeting held on 28.07.2022  
2. Previous Year figures have been regrouped whenever necessary.  
For Hindustan Bio Sciences Limited  
J.Manu Varma  
Director  
(DIN: 00816435)  
Place: Hyderabad  
Date : 28.07.2022